NASDAQ: AKBAAkebia Therapeutics Inc Stock
$1.37+0.01 (+0.74%)
Updated Apr 23, 2024
AKBA Price
$1.37
Fair Value Price
N/A
Market Cap
$286.84M
52 Week Low
$0.65
52 Week High
$2.48
P/E
-4.89x
P/B
-9.38x
P/S
1.19x
PEG
N/A
Dividend Yield
N/A
Revenue
$194.62M
Earnings
-$51.93M
Gross Margin
61.9%
Operating Margin
-23.58%
Profit Margin
-26.7%
Debt to Equity
-8.9
Operating Cash Flow
-$23M
Beta
1.49
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AKBA Overview
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AKBA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKBA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AKBA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AKBA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AKBA due diligence checks available for Premium users.
Be the first to know about important AKBA news, forecast changes, insider trades & much more!
AKBA News
Valuation
AKBA fair value
Fair Value of AKBA stock based on Discounted Cash Flow (DCF)
Price
$1.37
Fair Value
-$0.01
Undervalued by
25,195.54%
AKBA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AKBA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.89x
Industry
16.46x
Market
41.92x
AKBA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-9.38x
Industry
5.93x
AKBA's financial health
Profit margin
Revenue
$56.2M
Net Income
$614.0k
Profit Margin
1.1%
AKBA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AKBA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$241.7M
Liabilities
$272.3M
Debt to equity
-8.9
AKBA's short-term assets ($118.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKBA's long-term liabilities ($172.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKBA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AKBA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
$0.0
Financing
-$1.3M
AKBA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKBA vs Biotech Stocks
Akebia Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.